SCHEMBL5403777

SCHEMBL5403777

COc1ccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)N(C)c2ccco2)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
OPRK1 P41145 1/20 0.41
POLB P06746 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402772 0.94 ALDH1A1 (0.41) ALDH1A1TP53HPGDMAPK1CYP1A2
SCHEMBL5417110 0.94 APP (0.42) ALDH1A1TP53HPGDMAPK1CYP1A2
SCHEMBL5402208 0.88 SMN1; SMN2 (0.43) ALDH1A1HPGDLMNASMN1; SMN2POLB
SCHEMBL5409396 0.88 RAB9A (0.43) SMN1; SMN2POLBNPC1RAB9AL3MBTL1
SCHEMBL5399042 0.88 LPAR1 (0.39) TP53LMNASMN1; SMN2RAB9AL3MBTL1
SCHEMBL5392883 0.86 HSD17B10 (0.40) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL5403781 0.84 ALDH1A1 (0.52) ALDH1A1TP53HPGDMAPK1CYP1A2
SCHEMBL5398272 0.83 ALDH1A1 (0.40) ALDH1A1KDM4EPOLBNPC1RAB9A
SCHEMBL5402529 0.83 FFAR1 (0.43) TP53SMN1; SMN2POLBNPC1RAB9A
SCHEMBL5414355 0.83 LTB4R (0.42) ALDH1A1HPGDLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB ALDH1A1 1256/4885TP53 32/4885HPGD 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.